AVNS vs. ENOV, ESTA, CDRE, ZJYL, SMTI, INGN, LAKE, CLGN, APT, and MLSS
Should you be buying Avanos Medical stock or one of its competitors? The main competitors of Avanos Medical include Enovis (ENOV), Establishment Labs (ESTA), Cadre (CDRE), Jin Medical International (ZJYL), Sanara MedTech (SMTI), Inogen (INGN), Lakeland Industries (LAKE), CollPlant Biotechnologies (CLGN), Alpha Pro Tech (APT), and Milestone Scientific (MLSS). These companies are all part of the "surgical appliances & supplies" industry.
Avanos Medical (NYSE:AVNS) and Enovis (NYSE:ENOV) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, community ranking, earnings, analyst recommendations and valuation.
Avanos Medical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, Enovis has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500.
In the previous week, Avanos Medical had 6 more articles in the media than Enovis. MarketBeat recorded 10 mentions for Avanos Medical and 4 mentions for Enovis. Enovis' average media sentiment score of 1.35 beat Avanos Medical's score of 0.05 indicating that Enovis is being referred to more favorably in the news media.
Enovis has a net margin of -4.51% compared to Avanos Medical's net margin of -9.15%. Avanos Medical's return on equity of 4.10% beat Enovis' return on equity.
Avanos Medical received 59 more outperform votes than Enovis when rated by MarketBeat users. However, 60.00% of users gave Enovis an outperform vote while only 54.97% of users gave Avanos Medical an outperform vote.
95.2% of Avanos Medical shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 3.9% of Avanos Medical shares are owned by insiders. Comparatively, 2.4% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Enovis has higher revenue and earnings than Avanos Medical. Enovis is trading at a lower price-to-earnings ratio than Avanos Medical, indicating that it is currently the more affordable of the two stocks.
Enovis has a consensus price target of $75.43, suggesting a potential upside of 50.14%. Given Enovis' stronger consensus rating and higher probable upside, analysts clearly believe Enovis is more favorable than Avanos Medical.
Summary
Enovis beats Avanos Medical on 11 of the 18 factors compared between the two stocks.
Get Avanos Medical News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avanos Medical Competitors List
Related Companies and Tools
